AstraZeneca
oncology and total revenue in driven by global demand for key medicines oncology key dynamics strong demand across indications and lengthening dot sustained leadership in demand growth in us and continued impact demand from in us in sustained leadership driven by us and established soc in her and her low encouraging early adoption in agnostic new market leader in altered population new indications us laura and duo her gastric and her other regulatory us priority review echo gall a | AstraZeneca
Company
Deck Type
Deck date
November 2024
Slide
14 of 38
Related slides by other companies
Investor Presentation
October 2023
Investor Presentation
May 2022
Results
February 2024
Investor Presentation
December 2023
Other recent decks by AstraZeneca
Results
February 2025
Results
November 2024
Investor Event
September 2024
Results
February 2024
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2024 Slidebook.io